Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company’s lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis.
The stocks founds in the One Hot Stock category use stocks that are in long term, short term trends and are early in the buy signal trend. Suggested buy prices are listed with a price “or better”. Or better means anything lower than the buy price listed. (Learn about order types here). This is a confirmation strategy that waits for the stock to make a move then a trader enters the trend at specific prices. In many cases stocks that are in up trends tend to continue the overall trend direction and the prior trend is the path of least resistance. To learn more about trend following as well as reversal strategies you can go here.
